| Literature DB >> 35956931 |
Rafael G Araújo1, Natalia Rodríguez Zavala2, Carlos Castillo-Zacarías3, Mario E Barocio4, Enrique Hidalgo-Vázquez4, Lizeth Parra-Arroyo4, Jesús Alfredo Rodríguez-Hernández4, María Adriana Martínez-Prado2, Juan Eduardo Sosa-Hernández1, Manuel Martínez-Ruiz1, Wei Ning Chen5, Damià Barceló6,7,8, Hafiz M N Iqbal1,4, Roberto Parra-Saldívar1,4.
Abstract
Bionanocomposites based on natural bioactive entities have gained importance due to their abundance; renewable and environmentally benign nature; and outstanding properties with applied perspective. Additionally, their formulation with biological molecules with antimicrobial, antioxidant, and anticancer activities has been produced nowadays. The present review details the state of the art and the importance of this pyrrolic compound produced by microorganisms, with interest towards Serratia marcescens, including production strategies at a laboratory level and scale-up to bioreactors. Promising results of its biological activity have been reported to date, and the advances and applications in bionanocomposites are the most recent strategy to potentiate and to obtain new carriers for the transport and controlled release of prodigiosin. Prodigiosin, a bioactive secondary metabolite, produced by Serratia marcescens, is an effective proapoptotic agent against bacterial and fungal strains as well as cancer cell lines. Furthermore, this molecule presents antioxidant activity, which makes it ideal for treating wounds and promoting the general improvement of the immune system. Likewise, some of the characteristics of prodigiosin, such as hydrophobicity, limit its use for medical and biotechnological applications; however, this can be overcome by using it as a component of a bionanocomposite. This review focuses on the chemistry and the structure of the bionanocomposites currently developed using biorenewable resources. Moreover, the work illuminates recent developments in pyrrole-based bionanocomposites, with special insight to its application in the medical area.Entities:
Keywords: Serratia marcescens; bionanocomposites; biorenewable resources; prodigiosin; pyrrolic compounds
Mesh:
Substances:
Year: 2022 PMID: 35956931 PMCID: PMC9370345 DOI: 10.3390/molecules27154982
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1Bionanocomposites: Polymeric materials produced by bioprocesses (plants or microorganisms) based on nanostructure of materials derived from self-organization.
Figure 2Bionanocomposites: Versatility and their applications in different industries.
Figure 3Examples of natural prodiginines: Prodigiosin (A), Cycloprodigiosin (B), Undecylprodigiosin (C), Metacycloprodigiosin (D), Butyl-meta-cycloprodigiosin (E), and Prodigiosin R1 (F).
Prodigiosin producing bacteria reported in literature.
| Microorganism | Origin | Prodiginine Type | Microorganism | Origin | Prodiginine Type |
|---|---|---|---|---|---|
| Semi-arid soil around banana trees | Prodigiosin | N/A | Undecylprodigiosin | ||
| Pristine soil sample collected from the cavy area of Miroc mountain in eastern Serbia | Undecylprodigiosin | N/A | Undecylprodigiosin | ||
| From a mold and tofu sample | Prodigiosin | Sediment samples in Brazil | Nonylprodigiosin | ||
| N/A | Undecylprodigiosin | From rhizospheric soil in different sites of Salem and Namakkal, India | Prodigiosin (possible) | ||
| N/A | Butylcycloheptylprodigiosin and Undecylprodigiosin | N/A | Prodigiosin | ||
| From Lahul and Spiti region in Himachal Padresh, India | Prodigiosin | N/A | Prodigiosin | ||
| From clam samples collected form Temsah Lake, Egypt | Prodigiosin | From kitchen waste | Prodigiosin | ||
| Soil sample from a tannery in Chennai, Tamilnadu, India. | Prodigiosin | From soil sample collected in Thailand | Metacycloprodigiosin |
N/A: not applicable.
Recent antibacterial activity of prodigiosin reported in literature.
| Prodigiosin Source | Concentration | Bacteria | Parameter of | Value | Reference |
|---|---|---|---|---|---|
| Chiffon stained by prodigiosin |
| AATCC 100 | 95 | [ | |
|
| 97 | ||||
| Satin stained by prodigiosin |
| 91 | |||
|
| 84 | ||||
| Linen stained by prodigiosin |
| 97 | |||
|
| 70 | ||||
| Dacron stained by prodigiosin |
| 90 | |||
|
| 84 | ||||
| Gabardine stained by prodigiosin |
| 19 | |||
|
| 15 | ||||
|
| Silk pH 2.1 |
| Antibacterial rate | 93.17% | [ |
|
| 25.12% | ||||
| Silk pH 8.1 |
| 87.80% | |||
|
| 14.70% | ||||
|
| 25–400 µg/mL |
| IC50 | 51.17 µg/mL | [ |
|
| 51.54 µg/mL | ||||
|
| 26.18 µg/mL | ||||
|
| 33.61 µg/mL | ||||
|
| 56.56 µg/mL | ||||
|
| 50.81 µg/mL | ||||
|
| 69.71 µg/mL | ||||
|
| 48.63 µg/mL | ||||
|
| 66.98 µg/mL | ||||
|
| 44.20 µg/mL | ||||
|
| 20.31 µg/mL | ||||
|
| 25 µg/mL |
| Maximum zone of inhibition (mm) | 17 | [ |
|
| 15 | ||||
|
| 250 μg/mL |
| Maximum zone of inhibition (mm) | 20 ± 0.33 | [ |
|
| 20 ± 0.0 | ||||
|
| 20 ± 0.88 | ||||
|
| 22 ± 0.41 | ||||
| 500 μg/mL |
| 21 ± 0.00 | |||
|
| 22 ± 0.33 | ||||
|
| 20 ± 0.33 | ||||
|
| 27 ± 0.82 | ||||
|
| 24.48 μg/mL |
| Minimal inhibitory concentration (MIC) | 2.56 μg/mL | [ |
Antifungal activity of prodigiosin.
| Prodigiosin Source | Concentration | Fungi | Parameter of Antifungal | Value | Reference |
|---|---|---|---|---|---|
|
| 3.8 µM |
| IC50 | 3.8 µM | [ |
| 27.3 μM |
| IC50 | 27.3 μM | ||
| 10 μM |
| Minimum inhibitory concentration (MIC) | 10 μM | ||
| 50 μM |
| Minimum inhibitory concentration (MIC) | 50 μM | ||
|
| Crude extract from rhizosphere of |
| Percent inhibition | 71.33 | [ |
|
| Percent inhibition | 61.33 | |||
|
| Percent inhibition | 49.33 | |||
|
| Percent inhibition | 48.66 | |||
|
| Percent inhibition | 31 | |||
|
| 450 µg/mL |
| Percent inhibition | 29.27 | [ |
| 1000 µg/mL |
| Percent inhibition | 100 | ||
|
| - |
| Percent inhibition | 40 | [ |
Antitumoral activity of prodigiosin against different cancer cell lines.
| Cancer Type | Cell Line | Mechanism | IC50 | Units | Reference |
|---|---|---|---|---|---|
| Blood/Leukemia | K562 | Increased activity of caspases -3, -8, -9, reactive oxygen species, inhibition of autophagy and apoptosis induction. | >500 | µM | [ |
| HL-60 | Apoptosis induction | 1.7 | µg/mL | [ | |
| Wt-p53Molt-4 | Caspase-3-dependent apoptosis | 1.3 | µM | [ | |
| Brain | GBM8401 | ER stress/autophagy | 7.36 | µM | [ |
| U87MG | ER stress/autophagy | 12.29 | µM | ||
| Breast | MDA-MB-231 | ER stress; Wnt/β-catenin; JNK/MAPK/RAD51 | 62.52 | nM | [ |
| MDA-MB-468 | Inhibit Wnt/β-catenin | 261.2 | nM | ||
| MCF-7 | Apoptosis induction | 5.1 | µg/mL | [ | |
| MCF-7 | Mitogen-activated protein kinase regulators, pH modulators, DNA cleavage agents and cell cycle inhibitors | 0.04 | µg/mL | [ | |
| MDA-MB-231 | Decreased the levels of mTOR and HSP90α expression and transcription | 2.1 | nM | [ | |
| Urothelial | RT-112 | Dysregulation of lysosomal function and reduction of cathepsin B and L activity | 675 | nM | [ |
| Colorectal | DLD1 | c-Jun/ΔNp73/p73/apoptosis; Lysosomal acidification | >1.6 | µM | [ |
| HCT116 | c-Jun/ΔNp73 p73 activation | 4 | µM | ||
| SW480 | c-Jun/ΔNp73 p73 activation | µM | |||
| SW-620 | Apoptosis | 0.273 | µM | ||
| HCT116; SW480 | Blocking autophagosome–lysosome fusion and maturation of lysosomal cathepsin | >0.1 | µM | [ | |
| WiDr | Mitogen-activated protein kinase regulators, pH modulators, DNA cleavage agents and cell cycle inhibitors | 0.05 | µg/mL | [ | |
| Liver | HepG2 | Antiproliferative effects | 12.64 | µg/mL | [ |
| HepG2 | Mitogen-activated protein kinase regulators, pH modulators, DNA cleavage agents and cell cycle inhibitors | 0.04 | µg/mL | [ | |
| Lung | A549 | PI3K-p85/Akt/mTOR; PKB/SKP2/p27 | 10 | µM | [ |
| CNE2, NP69 | PKB/SKP2/p27 | 4 and 0.35 | mg/L | [ | |
| NCHI-292 | Apoptosis induction | 3.6 | µg/mL | [ | |
| A549 | Mitogen-activated protein kinase regulators, pH modulators, DNA cleavage agents and cell cycle inhibitors | 0.06 | µg/mL | [ | |
| Prostate | PC3 | Intrinsic apoptosis | >10 | µg/mL | [ |
| Trophoblast | JEG3 | Intrinsic apoptosis | >10 | µg/mL | |
| Uterus | Hela | Antiproliferative effects | 12.75 | µg/mL | [ |
| Gingival squamous carcinoma | OECM1 | Cyclin D1 inhibition, arresting cell cycle in G0/G1 phase | 1.59 ± 0.77 | μM | [ |
| Tongue | SAS | cyclin D1 inhibition, arresting cell cycle in G0/G1 phase | 3.25 ± 0.49 | μM | |
| Uterus | Hela | Intrinsic apoptosis | 0.5–2.1 | μg/mL | [ |